Skip to content
MARKETS / NASDAQ / TMCI
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · MID CAP

Treace Medical Concepts, Inc. TMCI

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$212.7M
▲ 1.6% YoY
$-59.0M
$-29.5M
In brief

What this company does

The company markets and sells its products in the United States primarily through a direct employee sales force supplemented by independent sales agencies, reaching approximately 8,000 surgical podiatrists and 2,600 orthopaedic surgeons with foot and ankle specializations. In most cases, the company maintains redundant manufacturing capabilities for each of its products and assembles a portion of its sterile kits at its corporate headquarters. As of December 31, 2025, the company had approximately 450 full-time employees. As of December 31, 2025, the company leased approximately 125,000 square feet for its corporate headquarters located in Ponte Vedra, Florida, under a lease agreement that terminates in July 2032.

Written from the business description in TREACE MEDICAL CONCEPTS, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.

Growth
USD 212.7M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 212.7 · Net income -59.0
80M160M-20M-40M2019202020212022202320242025
Compound annual growth
+14.5%
+30.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +30.0% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−28 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -25.5% · Net -27.7%
-10%-20%-30%2019202020212022202320242025
ROE
FY2025 · ROE -58.9%
-50%-100%-150%2019202020212022202320242025

Each USD of equity lost 59 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -29.5
-20M-40M2019202020212022202320242025

Total assetsUSD 190.6M
EquityUSD 87.3M
CashUSD 10.7M
Gross debtUSD 57.3M
Net debtUSD 46.6M
Current ratio4.31×

Net debt stands at 53% of equity.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 2025202420232022202120202019
Revenue $B0.20.20.20.10.10.10.0
Operating income $B−0.1−0.1−0.1−0.0−0.00.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.00.0−0.0
Income tax $B0.00.00.00.00.00.00.0
Net income $B−0.1−0.1−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.93−0.90−0.81−0.77−0.43−0.12−0.13
Dividend / sh $·······
Payout %·······
ROE %−58.9−44.4−49.9−55.7−43.8−186.3−134.9
Shares out B··0.060.060.05··

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 33 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 62 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inFlorida
Fiscal year endsDecember 31
Data on record since2019

Share this section

Download image